Andrew Combs serves as Executive at Prelude Therapeutics Inc, where they oversee executive responsibilities. Since joining the company, Andrew Combs has executed 5 insider transactions totaling $113.9K, demonstrating a bullish approach to their equity position. Their most recent transaction on Feb 4, 2026 involved receiving (via award) 230,000 shares valued at $0.
Andrew Combs currently holds 230,000 shares of Prelude Therapeutics Inc (PRLD), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew Combs has been a net buyer of PRLD stock. They have purchased $113.9K and sold $0 worth of shares.
Andrew Combs's most recent insider trade was on Feb 4, 2026, when they sold 230,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $1.89 |
| Discretionary |
| Dec 14, 2021 | PRLD | $46.4K | Purchase | 4,000 | $11.60 | Discretionary |
| Dec 13, 2021 | PRLD | $48.5K | Purchase | 4,000 | $12.12 | Discretionary |
| Sep 29, 2020 | PRLD | $19.0K | Purchase | 1,000 | $19.00 | Discretionary |